Skip to main content

Table 1 Baseline patient characteristics at McGill, at Hillel Yaffe and when data was pooled. No statistically significant differences were found between the groups in terms of age, gender distribution, U/S determined nodule size or Bethesda score (p > 0.05 for each category at both centres, 95% CI)

From: Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: a retrospective chart review

  Control Molecular Testing
Age (yrs) 54.1 (48.4–59.8) 49.2 (46.0–53.5)
McGill 52.3 (45.8–58.7) 48.7 (45.3–52.1)
Hillel Yaffe 61.7 (47.2–76.3) 51.9 (41.2–62.2)
Female gender (%) 80.3 86.8
McGill 74.9 73.6
Hillel Yaffe 85.7 100
Nodule size (cm) 1.9 (1.5–2.2) 1.8 (1.6–2.0)
McGill 1.9 (1.6–2.2) 1.8 (1.6–2.0)
Hillel Yaffe 1.4 (0.9–2.5) 1.6 (1.3–2.2)
Bethesda Score of VI (%) 52.8 48.8
McGill 44.8 45.8
Hillel Yaffe 64.3 85.7